Pharmaceutical giant Novo Nordisk (NYSE ... which target diabetes and obesity, respectively. In one head-to-head study, Zepbound even proved superior to Wegovy in helping patients shed excess ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work ...

Shares in Novo Nordisk were up nearly 12% today ... GIP/GLP-1 agonist tirzepatide. Lilly's obesity therapy recently outperformed Wegovy in a head-to-head weight loss study, while CagriSema's ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry. The Danish pharma giant ...

Brian Finan, head of obesity research at Novo Nordisk, said the company is "excited about the opportunity to advance Embark Biotech's lead programme" and looks forward to "co-creating novel ...

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE ... oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...

The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of blockbuster obesity drug Wegovy. European ...

Such a highly watched spot instantly turned the spotlight on the ambitious company, at the same time making investors nervous about other obesity drug developers. Novo Nordisk and Eli Lilly are ...